Participants 45 92 7
children with pervasive developmental disorders
Participants 209 256 7
children with pervasive developmental disorders
Participants 265 508 7
Twenty-four children (aged 5-17 years) with pervasive developmental disorders and co-morbid disruptive behavior who responded favorably to open-label treatment with risperidone as part of a previously described controlled discontinuation study
Participants 1475 1522 7
children with pervasive developmental disorders
